APR 2 4 2001 CU-2140 TJK
TAND TRANSPORTS OFFICE

ANTIGEN

THE UNITED STATES PATENT AN

In re Application of: Raa et al.)	NOVEL, NON-ANTIGENIC,
)	MUCOSAL ADJUVANT
Serial No.: 09/511,582)	FORMULATION WHICH
)	MODULATES THE
Filed: February 23, 2000)	EFFECTS OF SUBSTANCES,
)	INCLUDING VACCINE
)	ANTIGENS, IN CONTACT
)	WITH MUCOSAL BODY
)	SURFACES
)	
)	Group Art Unit: 1643
)	Examiner: J Stucker

TRANSMITTAL LETTER

Assistant Commissioner for Patents Washington, D.C. 20231

Sir:

Please find enclosed the following in the above referenced patent application:

Executed Revocation of Power, Power of Attorney and Notice of Change 1. of Correspondence Address.

Please acknowledge receipt of the above by returning the enclosed stamped, selfaddressed receipt postcard.

Please charge any additional fees to Deposit Account No. 23-2126. A displicate of this transmittal is enclosed.

Date:

Wildman, Harrold, Allen & Dixon

0225 West Wacker Drive Chicago, IL 60606 Ph. (312) 201-2000 Fax (312) 201-2555

Respectfully submitt

By:

r, Reg. No. 35,567

CERTIFICATE OF MAILING

I hereby certify that this paper is being deposited with the United States Postal Service as first class mail in an envelope addressed to the Assistant Commissioner for patents, Washington, D.C. 20231 on

AUTHORISATION

The board of Biotec ASA hereby authorise each Mr. Gunnar Rørstad and Ms. Kirsti Nikolaisen to sign and act on behalf of the company in patent and trademark issues relating to the group's business, including, but not limited to, patents and trademark applications.

This authorisation is valid as from 6 October 2000, and until it is withdrawn in writing.

Oslo, 6 October 2000

Stein Holst Annexstad

Chairman

Jan Raa

Boardmember